Organon & Co. (OGN) Scheduled to Post Earnings on Thursday

Organon & Co. (NYSE:OGN) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Organon & Co. to post earnings of $0.94 per share for the quarter. Organon & Co. has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The firm’s quarterly revenue was down .1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.31 earnings per share. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Trading Up 1.7 %

Shares of OGN stock opened at $17.46 on Tuesday. The company has a market cap of $4.49 billion, a P/E ratio of 4.49, a PEG ratio of 0.77 and a beta of 0.84. The stock has a 50 day simple moving average of $19.63 and a two-hundred day simple moving average of $20.12. The company has a debt-to-equity ratio of 60.05, a quick ratio of 1.17 and a current ratio of 1.64. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $23.10.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were issued a $0.28 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.12 dividend on an annualized basis and a yield of 6.42%. Organon & Co.’s payout ratio is currently 28.79%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their target price for the stock from $18.00 to $20.00 in a report on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.